Everolimus in Anaplastic Thyroid Cancer: A Case Series

Ethan J. Harris 1, Glenn J. Hanna 1, Nicole Chau 1, Guilherme Rabinowits 2, Robert Haddad 1, Danielle N. Margalit 1, Jonathan Schoenfeld 1, Roy B. Tishler 1, Justine A. Barletta 2, Matthew Nehs 3, Pasi Janne 1, Julian Huang 1,4, Phillip Groden 5, Alec Kacew 1 and Jochen Lorch 1*

1 Dana-Farber Cancer Institute, Boston, MA, United States, 2 Miami Cancer Institute, Miami, FL, United States, 3 Brigham and Women’s Hospital, Boston, MA, United States, 4 Yale School of Medicine, New Haven, CT, United States, 5 Icahn School of Medicine at Mount Sinai, New York, NY, United States

Background: Anaplastic thyroid cancer (ATC) is a very aggressive disease and accounts for over 50% of thyroid-cancer-related deaths. mTOR inhibition has shown anti-tumor activity in ATC. We report our experience treating patients with ATC with everolimus off-protocol.

Methods: Patients with confirmed ATC and treated with everolimus at DF CI were identified and reviewed retrospectively. NexGen sequencing was performed, and radiologic responses were correlated with mutational profile.

Results: Five patients were treated from 2013 to 2016. Three patients had a response, which included one patient who achieved a partial response for 27.9 months, and two patients who had stable disease for 3.7 and 5.9 months, respectively. Genomic analysis was available in two patients and revealed that the partial responder had mutations involving the PI3K/mTOR pathway.

Conclusion: Everolimus has anti-tumor activity in ATC, and responses may correlate with mutations involving the PI3K/mTOR pathway. Further studies are warranted.

Keywords: anaplastic thyroid cancer (ATC), precision medicine, mTOR inhibition in head and neck cancer, exceptional responder, PI3K mTOR

INTRODUCTION

Anaplastic thyroid cancer (ATC) constitutes only 1–2% of all thyroid cancer cases; however, it is one of the most lethal types of cancer and has a uniformly poor prognosis with a median survival of 3–5 months (1). It accounts for more than 50% of all thyroid cancer-related deaths due to its aggressive biology, which is characterized by early hematogenous metastasis. It may arise from differentiated thyroid cancer TC (2), occurs more frequently in men, and typically afflicts the elderly.

There is currently no standard treatment for metastatic ATC. Weekly taxane with or without platinum may be used, but these agents have an unknown impact on overall survival (3, 4). In patients with the activating BRAFV600E mutation, the combination of the BRAF and MEK inhibitors dabrafenib and trametinib, has recently shown promising activity in ATC (5, 6). Aside from that group of patients, treatment success has been largely disappointing, highlighting the need for more effective treatment regimens.

Genomic analysis has found that ATC has a high mutational burden, which contrasts with the genomic landscape of differentiated thyroid cancer, such as papillary TC, and poorly differentiated...
thyroid cancer (PDTC) (7). In ATC, TERT, TP53, SWI/SNF subunits, histone methyltransferases, and the PI3K/mTOR/AKT pathway were frequently altered. Within the PI3K/AKT/mTOR pathway, mutations in PIK3CA, AKT, mTOR, PTEN, TSC1, TSC2, and NFI were more common in ATC than PDTC, indicating the pathway plays a central role in disease progression (8).

Rapamycin and its analogs, such as everolimus, are allosteric inhibitors of the mTOR pathway and specifically inhibit activation of the mTOR complex 1. Everolimus is FDA approved to treat various cancers, including breast and renal cell carcinoma. We have previously treated seven patients with ATC in an exploratory cohort within a phase 2 study using everolimus and had two responses (9). Another phase 2 study using everolimus in patients with thyroid cancer included 6 patients with anaplastic histology, and one partial response was observed (10). Here, we report our experience with everolimus given off-protocol in 5 patients with ATC.

**MATERIALS AND METHODS**

**Chart Review**

The DFCI's Institutional Review Board approved this retrospective case series and chart review for all patients with ATC who were treated with everolimus off-protocol. All patients provided written consent, and all patients from 2013 to 2016 were included in this analysis. Investigators assessed tumor response using radiologic imaging and confirmed them using the corresponding radiologist reports. Partial responses were calculated starting from the first scans demonstrating a response, and stable disease was calculated from the start of everolimus. Overall survival was calculated from the start of everolimus until death. All durations were calculated in months.

**Genomic Sequencing**

Patients who provided written consent for tumor sequencing had fixed-formalin paraffin embedded slides prepared for total gDNA extraction. ATC pathology was confirmed prior to extraction. The sample's gDNA concentration was quantified and, if sufficient, underwent library construction, subjected to qPCR, and analyzed based on the OncoPanel_y1 bait set (Oncopanel), a database of 275 cancer genes and 91 introns across 30 genes with known or potential importance in cancer, using an Illumina Hiseq 2500. Picard tools, which align and de-multiplex read pairs, and the GATK tool, which localizes realignment, were used (11, 12).

**Tissue Diagnosis**

An expert in thyroid pathology (JB) reviewed all ATC cases in this study and confirmed the diagnoses.

**RESULTS**

Five patients who had ATC and were treated with everolimus off-protocol were identified. Four patients were male and one was female; the median age at diagnosis was 75 (range: 62–79). Three patients had distant metastatic disease at the time of diagnosis, and two had unresectable locoregional disease. One patient had an associated component of papillary thyroid cancer in her tumor specimen. Two patients received carboplatin and paclitaxel with radiotherapy prior to starting everolimus, and one patient, who had papillary thyroid cancer 12 years prior to her ATC diagnosis, was initially treated with radioactive iodine (RAI), and then a resection in the thyroid bed for a local recurrence.

All patients started treatment taking 10 mg of everolimus every day. Due to toxicities such as fatigue and pneumonitis, patients could receive 10 mg of everolimus every other day. Overall, patients took everolimus for a median of 5.3 months (range: 0.8–29.5). Overall, median survival in this cohort was 7.4 months (Figure 1). One patient had a partial response for 27.9 months. This patient's treatment course was complicated by mTOR-induced pneumonitis. Initially, the side effects from everolimus were managed with treatment breaks, but after 12.6 months of treatment, her dose was reduced to 10 mg every other day. This allowed her to continue with everolimus for another 16.9 months before her treatment was discontinued. CT scans revealed that her disease was well controlled at the time of discontinuation of the drug (Figures 2A–C). Two other patients had stable disease for 3.7–5.9 months, respectively. One patient had a mixed response, and another patient had disease progression.

Genetic analysis demonstrated the BRAFV600E mutation and two known activating PI3K mutations (PIK3CAE970K and PIK3CAE542K) in the partial responder. Additionally, the tissue's ATC diagnosis was confirmed (Figures 2D,E). Among the two patients who had stable disease, sequencing of the primary tumor revealed the BRAFV600E mutation in one case; no sequencing could be performed in the other case due to lack of sufficient material (Table 1). Copy number alterations were also documented (Figure 3).

**DISCUSSION**

ATC remains one of the deadliest forms of cancer with no generally accepted standard of care. In this retrospective analysis,
FIGURE 2 | Radiologic and histologic imaging of the patient who achieved a partial response (#3).

TABLE 1 | Patient population and treatment results.

|          | 1′ | 2  | 3′  | 4′ | 5   |
|----------|----|----|-----|----|-----|
| Histology| ATC| ATC| ATC with aPTC | ATC | ATC |
| Age at diagnosis (y) | 75 | 62 | 79 | 78 | 63 |
| Gender | Male | Male | Female | Male | Male |
| Stage | M | M | M | LR | LR |
| Prior treatment | None | Carboplatin and paclitaxel with radiation | RAI and thyroidectomy | None | Carboplatin and paclitaxel with radiation |
| Mutations | N/A | N/A | PIK3CA E542K | PIK3CA E970K | BRAF V600E |
| Duration prescribed everolimus (mo) | 0.8 | 1.7 | 29.5 | 5.3 | 5.9 |
| Best radiologic response, length (mo) | PD | MR | PR, 27.9 | SD, 3.7 | SD, 5.9 |
| Overall survival (mo) | D, 0.8 | D, 2.8 | D, 39.2 | D, 7.4 | D, 16.5 |

1First-line of treatment 2only actionable mutations included, 3EMR did not capture patient’s final month alive, was not included in analysis, 4Treatment for PTC, prior to ATC diagnosis, 5Continued everolimus after radiologic PD, aPTC, associated component of papillary thyroid carcinoma; M, metastatic; LR, locoregional; RAI, radioactive iodine; PD, progressive disease; MR, mixed response; PR, partial response; SD, stable disease; D, deceased.
Missense mutations

| Gene  | Patient #3 | Patient #4 |
|-------|------------|------------|
| BRAF  |            |            |
| PIK3CA|            |            |
| CHEK2 |            |            |
| EXT1  |            |            |
| DMD   |            |            |
| MYCL  |            |            |
| SF1   |            |            |
| TCP7L1|            |            |
| AKT1  |            |            |
| PRPF8 |            |            |
| SOX9  |            |            |

Copy number alterations

| Gene   | Patient #3 | Patient #4 |
|--------|------------|------------|
| PDCD1LG2|            |            |
| CRTC2  |            |            |
| KDM6B  |            |            |
| RB1    |            |            |
| NFE2L2 |            |            |
| JAK2   |            |            |
| FUSDM13|            |            |
| REL    |            |            |
| MIDM4  |            |            |
| BCL2L12|            |            |
| RUNX1  |            |            |
| FH     |            |            |
| CD274  |            |            |
| NKK2-1 |            |            |
| NBN    |            |            |
| B2M    |            |            |
| CD58   |            |            |
| PTEN   |            |            |
| CDC73  |            |            |
| CDKN1B |            |            |
| SUZ12  |            |            |
| RPL26  |            |            |
| CDK1   |            |            |
| H3F3A  |            |            |
| RFWD2  |            |            |
| PMS1   |            |            |
| PHE3R1 |            |            |
| KRA3   |            |            |
| FRMD1  |            |            |
| AKT3   |            |            |
| NFKBIA |            |            |
| PIK3CB |            |            |
| NFKBIZ |            |            |
| SDHC   |            |            |
| MCL1   |            |            |
| IKF3   |            |            |
| PRKCI  |            |            |
| CDKN2A |            |            |
| CDKN2B |            |            |
| ASXL1  |            |            |
| RAD21  |            |            |
| GNAS   |            |            |
| PRKDC  |            |            |
| SRC    |            |            |
| FTK2   |            |            |
| NBN    |            |            |
| EXT1   |            |            |
| MYBL1  |            |            |
| MYC    |            |            |
| AURKA  |            |            |
| BCL2L1 |            |            |
| 2NPD2  |            |            |
| CDKN1A |            |            |
| PNRC1  |            |            |
| E2F1   |            |            |
| PMS2   |            |            |

Legend

MM: missense mutation, CG: copy gain, HD: heterozygous deletion, MBC: mean sequencing coverage, CNA: copy number alteration. Patient 3’s sample was from the lung, had a MBC of 168x, and an estimated 69% tumor purity. Patient 4’s sample was from the primary, had a MBC 192x, and an estimated 80% tumor purity.

1CNA analysis noted low level CG and HD of CDKN2A/B
2CNA analysis noted monosomy 6, borderline gains of 8q and 20, and HD of PMS2

FIGURE 3 | All genomic alterations of patients with sequencing data available.
we report 5 patients with ATC who underwent palliative treatment with everolimus. One patient had a partial response lasting for 27.9 months, and two patients had stable disease lasting 3.7–5.9 months, respectively. Overall, the median survival after diagnosis was 7.4 months in this cohort.

Chemotherapy is generally considered marginally effective, and documented responses to targeted therapies are rare. Tyrosine kinase inhibitors, which have significant activity in differentiated thyroid cancer (13–16), have been used with some success in ATC. In a report of 2 patients treated with Axitinib, one patient had a PR (17). In a phase II study with sorafenib, 4/10 patients with ATC had disease stability (40%) (18). Additionally, a multi-center trial found that 2/20 patients had a PR, lasting for 10–27 months, respectively, and 5/20 had SD (19). A single-arm phase II study using lenvatinib in thyroid cancers, including 17 patients with ATC, reported an objective response rate of 24% and median OS of 10.6 months (16). In a recent retrospective study of 5 patients with unresectable ATC treated with lenvatinib, Koyama et al. found that 3/5 had a PR, 5/5 had SD, and the cohort had an OS of 165 days (20). Pazopanib, a VEGF inhibitor, has weak activity in ATC; a multi-institutional study of 15 patients treated with pazopanib monotherapy did not have any confirmed RECIST responses (21).

Combination therapy with BRAF and MEK inhibitors has shown anti-tumor activity in ATC. A recently published clinical trial treating patients with BRAFV600E positive ATC with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) reported a 69% ORR (11/16) with long-lasting responses (6). Another BRAF inhibitor, vemurafenib, has had some success (22, 23). In contrast, we have previously reported one patient with a BRAFV600E and a PIK3CAH1047R mutation who failed to respond to everolimus or dabrafenib and trametinib, but responded to the combined regimens (24).

In a prior phase II study, we evaluated everolimus as a single agent in 7 patients with metastatic ATC (9). Among these 7 patients, two responded: one achieved an exceptional response and another had disease stability for 31 months. Both patients carried mutations involving the PI3K/mTOR pathway; genetic analysis of the exceptional responder’s tumor revealed a truncating TSC2 mutation, resulting in loss of negative regulation of mTOR signaling (25), and the other patient had a mutation in NFI, a regulator of TSC2 and mTOR, and in PIK3CA and mTOR (9).

Recent analyses have begun to elucidate the molecular drivers behind ATC tumorigenesis. TERT, TP53, and PIK3CA appear to be more frequently mutated than in other forms of thyroid cancer, including in poorly differentiated thyroid cancer (PDTC), which may present histologically and clinically similar to ATC. Sequencing 33 ATC and 84 PDTC tumor samples discovered that TERT and TP53 mutations have been reported in 73% of cases, but we did not find any in our samples. Additionally, PIK3CA mutations were present in 18% of ATC samples, but only in 2% of PDTCs, and PI3K/akt pathway abnormalities were found in 39% of ATC samples vs. 11% of PDTC (8).

The partial responder’s tumor was sequenced and revealed three somatic variants: PIK3CAH542K, a helical domain and hotspot mutation, PIK3CAK970K, a mutation in the PI3 kinase domain, and BRAFV600E, a common mutation in ATC (8, 26). Tumorigenesis in animal models indicate that activating PI3K mutations alone are not sufficient to trigger the development of ATC and therefore frequently occur in combination with other mutations, such as BRAFV600E. Cell culture data has demonstrated synergy in ATC when both genes were mutated, and it is thought that BRAF activation promotes ATC transformation and PIK3CA drives its growth (27). In our experience with everolimus from this case series and previously reported phase II data, PI3K/mTOR activating mutations were present in all cases with a durable response (9, 24, 25).

Interestingly, ATC rarely arises from differentiated TCs and form as metastases. In a study including 677 cases of ATC, only 6 cases demonstrated transformation at the metastatic sites (0.9%), and this cohort had the worst outcomes (28). The partial responder’s ATC was first diagnosed after a lobectomy, suggesting that she had an initially poorer prognosis than the typical patient with ATC.

Our study has several limitations: although all patients who underwent treatment with everolimus off-protocol at our institution were included in this retrospective analysis, the generalizability of our findings are limited due to the sample size and sequencing data. The disease’s rarity makes it challenging to study larger cohorts of patients with ATC. Some patients did not consent to genetic sequencing or did not have enough tumor tissue.

This case series adds to the existing evidence that everolimus has anti-tumor activity in ATC, and responses may correlate with mutations along the PI3K/mTOR axis. Further investigation is warranted.

**AUTHOR CONTRIBUTIONS**

EH and JL collected the data and analyzed it. All authors contributed to writing the manuscript.

**REFERENCES**

1. Nagiaah G, Hossain A, Mooney CJ, Parmentier J, Remick SC. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol. (2011) 2011:542358. doi: 10.1155/2011/542358
2. Van der Laan BEAM, Freeman JL, Tsang RW, Asa SL. The association of well-differentiated thyroid carcinoma with insular or anaplastic thyroid carcinoma; evidence for dedifferentiation in tumor progression. Endocr Pathol. (1993) 4:215. doi: 10.1007/BF02915464
3. Denaro N, Nigro CL, Russi EG, Merlano MC. The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer. OncoTargets Ther. (2013) 9:1231–41. doi: 10.2147/OTT.S66545
4. Shimaoka K, Schoenfeld DA, Dewys WD, Creech RH, Deconti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer (1985) 56:2155–60. doi: 10.1002/1097-0142(19851101)56:9<2155::AID-CNCR2820560903>3.0.CO;2-E
5. Agarwal R, Wang J, Wilson K, Barrett W, Morris JC. Response to targeted therapy in BRAF mutant anaplastic thyroid cancer. J Natl Compr Cancer Netw. (2016) 14:1203–7. doi: 10.6004/jnccn.2016.0130
6. Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. (2018) 36:7–13. doi: 10.1200/JCO.2017.73.6785

7. Agraval N, Akhani R, Aksoy BA, Ally A, Arachchi H, Asa SL, et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell (2014) 159:676–90. doi: 10.1016/j.cell.2014.09.050

8. Landi L, Ibrahimipasic T, Boucai L, Sinha R, Knauf JA, Shah RH, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. (2016) 126:1052–66. doi: 10.1172/JCI85271

9. Hanna G, Bussaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, et al. Genomic correlates of response to everolimus in aggressive radiodine-refractory thyroid cancer: a phase II study. Clin Cancer Res. (2018) 24:1546–53. doi: 10.1158/1078-0432.CCR-17-2297

10. Lim SM, Chang H, Yoon MJ, Hong YK, Kim H, Chung WY, et al. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. Ann Oncol. (2013) 24:3089–94. doi: 10.1093/annonc/mdt379

11. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics (2010) 26:589–95. doi: 10.1093/bioinformatics/btp698

12. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. (2010) 20:1297–303. doi: 10.1101/gr.107524.110

13. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet (2014) 384:319–28. doi: 10.1016/S0140-6736(14)60421-9

14. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab. (2010) 95:2588–95. doi: 10.1210/jc.2009-1923

15. Capdevila J, Trigo JM, Aller J, Manzano JL, Garcia-Adrián S, Zafon C, et al. Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC). Eur J Endocrinol. (2017) 177:309–17. doi: 10.1530/EJE-17-0243

16. Tahara M, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, et al. Lenvatinib for anaplastic thyroid cancer of all histologic subtypes. Eur Thyroid J. (2012) 36:7–13. doi: 10.1159/000485972

17. Bible KC, Suman VJ, Meneee ME, Smallridge RC, Molina JR, Maples WJ, et al. A multinational phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab. (2012) 97:3179–84. doi: 10.1210/jc.2012-1520

18. Ito Y, Onoda N, Ito K-I, Sugitani I, Takahashi S, Yamaguchi I, et al. Sorafenib for patients with differentiated thyroid cancer: a randomised, double-blind, phase 3 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab. (2012) 97:3179–84. doi: 10.1210/jc.2012-1520

19. Savvides P, Nagaiah G, Lavertu P, Fu P, Wright JJ, Chapman R, et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid (2013) 23:600–4. doi: 10.1080/thy.2012.0103

20. Koyama S, Miyake N, Fujiwara K, Morisaki T, Fukuhara T, Kitano H, et al. Lenvatinib for anaplastic thyroid cancer and lenvatinib-induced thyroid dysfunction. Eur Thyroid J. (2018) 7:139–44. doi: 10.1159/000485972

21. Bible KC, Suman VJ, Meneee ME, Smallridge RC, Molina JR, Maples WJ, et al. Genomic heterogeneity and exceptional response to dual pathway inhibition in anaplastic thyroid cancer. Clin Cancer Res. (2017) 23:2367–73. doi: 10.1158/1078-0432.CCR-16-2154-T

Conflict of Interest Statement: JL: Consulting, BMS; Research support, Novartis, BMS, Millennium, Bayer.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Harris, Hanna, Chau, Rabinowits, Haddad, Margolit, Schoenfeld, Weiner, Rosenberg et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.